BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

Search

Argenx SE

Avatud

SektorTervishoid

529.6 0.34

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

524.4

Max

533.2

Põhinäitajad

By Trading Economics

Sissetulek

751M

836M

Müük

730M

1.3B

P/E

Sektori keskmine

46.72

57.333

Aktsiakasum

0.72

Kasumimarginaal

64.112

Töötajad

1,599

EBITDA

37M

126M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-2.07% downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

8. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-4.3B

32B

Eelmine avamishind

529.26

Eelmine sulgemishind

529.6

Argenx SE Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. apr 2025, 23:44 UTC

Kuumad aktsiad

Stocks to Watch: Jacobs Solutions, Argenx

10. apr 2025, 23:39 UTC

Suurimad hinnamuutused turgudel

Argenx ADRs Gain, FDA Approves New Delivery Method of Existing Autoimmune Disease Treatment

Võrdlus sarnastega

Hinnamuutus

Argenx SE Prognoos

Hinnasiht

By TipRanks

-2.07% langus

12 kuu keskmine prognoos

Keskmine 438.33 EUR  -2.07%

Kõrge 545 EUR

Madal 223 EUR

Põhineb 6 Wall Streeti analüütiku instrumendi Argenx SE 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

5

Osta

0

Hoia

1

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.